Neurocrine Biosciences (NBIX) — insider trading
Health Care · NASDAQ
Neurocrine Biosciences (NBIX) has 124 reported SEC Form 4 insider transactions in our data, including 27 open-market sales among the most recent 100 (latest 2026-09-14).
Recent Form 4 transactions
Showing the 100 most recent of 124 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Boyer David W. | Officer (Chief Corp. Affairs Officer) | Open-market sale | 826 | $157.45 | $130.1K | Form 4 |
| 2026-09-14 | ABERNETHY MATT | Officer (Chief Financial Officer) | Open-market sale | 2,311 | $157.20 | $363.3K | Form 4 |
| 2026-09-11 | Onyia Jude | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 1,936 | $156.22 | $302.4K | Form 4 |
| 2026-09-11 | Onyia Jude | Officer (Chief Scientific Officer) | Grant / award / vesting | 3,587 | — | $0 | Form 4 |
| 2026-09-11 | Lippoldt Darin | Officer (Chief Legal Officer) | Shares withheld for taxes / exercise cost | 2,419 | $156.22 | $377.9K | Form 4 |
| 2026-09-11 | Lippoldt Darin | Officer (Chief Legal Officer) | Grant / award / vesting | 4,483 | — | $0 | Form 4 |
| 2026-09-11 | Keswani Sanjay Chandru | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 2,112 | $156.22 | $329.9K | Form 4 |
| 2026-09-11 | Keswani Sanjay Chandru | Officer (Chief Medical Officer) | Grant / award / vesting | 3,914 | — | $0 | Form 4 |
| 2026-09-11 | Gano Kyle | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 994 | $156.22 | $155.3K | Form 4 |
| 2026-09-11 | Gano Kyle | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 1,842 | — | $0 | Form 4 |
| 2026-09-11 | Gano Kyle | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 3,386 | $156.22 | $529.0K | Form 4 |
| 2026-09-11 | Gano Kyle | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 6,275 | — | $0 | Form 4 |
| 2026-09-11 | GORMAN KEVIN CHARLES | Director | Shares withheld for taxes / exercise cost | 7,839 | $156.22 | $1.22M | Form 4 |
| 2026-09-11 | GORMAN KEVIN CHARLES | Director | Grant / award / vesting | 14,343 | — | $0 | Form 4 |
| 2026-09-11 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Shares withheld for taxes / exercise cost | 2,419 | $156.22 | $377.9K | Form 4 |
| 2026-09-11 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Grant / award / vesting | 4,483 | — | $0 | Form 4 |
| 2026-09-11 | Cooke Julie | Officer (Chief Human Resources Officer) | Shares withheld for taxes / exercise cost | 1,936 | $156.22 | $302.4K | Form 4 |
| 2026-09-11 | Cooke Julie | Officer (Chief Human Resources Officer) | Grant / award / vesting | 3,587 | — | $0 | Form 4 |
| 2026-09-11 | Boyer David W. | Officer (Chief Corp. Affairs Officer) | Shares withheld for taxes / exercise cost | 1,936 | $156.22 | $302.4K | Form 4 |
| 2026-09-11 | Boyer David W. | Officer (Chief Corp. Affairs Officer) | Grant / award / vesting | 3,587 | — | $0 | Form 4 |
| 2026-09-11 | BENEVICH ERIC | Officer (Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 3,386 | $156.22 | $529.0K | Form 4 |
| 2026-09-11 | BENEVICH ERIC | Officer (Chief Commercial Officer) | Grant / award / vesting | 6,275 | — | $0 | Form 4 |
| 2026-09-11 | ABERNETHY MATT | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 2,709 | $156.22 | $423.2K | Form 4 |
| 2026-09-11 | ABERNETHY MATT | Officer (Chief Financial Officer) | Grant / award / vesting | 5,020 | — | $0 | Form 4 |
| 2026-09-09 | BENEVICH ERIC | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 3,194 | — | $0 | Form 4 |
| 2026-09-09 | BENEVICH ERIC | Officer (Chief Commercial Officer) | Open-market sale | 2,154 | $154.61 | $333.0K | Form 4 |
| 2026-09-09 | BENEVICH ERIC | Officer (Chief Commercial Officer) | Option exercise / conversion | 3,194 | $43.24 | $138.1K | Form 4 |
| 2026-09-02 | SHERWIN STEPHEN A | Director | Bona fide gift | 1,000 | — | $0 | Form 4 |
| 2026-08-04 | Onyia Jude | Officer (Chief Scientific Officer) | Bona fide gift | 2,409 | — | $0 | Form 4 |
| 2026-07-29 | Norwalk Leslie V | Director | Option exercise / conversion (derivative) | 842 | — | $0 | Form 4 |
| 2026-07-29 | Norwalk Leslie V | Director | Option exercise / conversion | 842 | $139.43 | $117.4K | Form 4 |
| 2026-07-28 | Norwalk Leslie V | Director | Open-market sale | 1,250 | $182.01 | $227.5K | Form 4 |
| 2026-07-10 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion (derivative) | 4,367 | — | $0 | Form 4 |
| 2026-07-10 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Open-market sale | 4,367 | $181.02 | $790.5K | Form 4 |
| 2026-07-10 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion | 4,367 | $106.02 | $463.0K | Form 4 |
| 2026-07-09 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-07-09 | Lippoldt Darin | Officer (Chief Legal Officer) | Open-market sale | 10,000 | $179.60 | $1.80M | Form 4 |
| 2026-07-09 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion | 10,000 | $81.49 | $814.9K | Form 4 |
| 2026-07-09 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion (derivative) | 8,433 | — | $0 | Form 4 |
| 2026-07-09 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Open-market sale | 8,433 | $178.72 | $1.51M | Form 4 |
| 2026-07-09 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion | 8,433 | $103.52 | $873.0K | Form 4 |
| 2026-07-08 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion (derivative) | 2,737 | — | $0 | Form 4 |
| 2026-07-08 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Open-market sale | 2,737 | $178.54 | $488.7K | Form 4 |
| 2026-07-08 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion | 2,737 | $103.52 | $283.3K | Form 4 |
| 2026-07-07 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion (derivative) | 3,401 | — | $0 | Form 4 |
| 2026-07-07 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Open-market sale | 3,401 | $178.57 | $607.3K | Form 4 |
| 2026-07-07 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion | 3,401 | $103.52 | $352.1K | Form 4 |
| 2026-06-29 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 1,690 | — | $0 | Form 4 |
| 2026-06-29 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 8,110 | — | $0 | Form 4 |
| 2026-06-29 | Lippoldt Darin | Officer (Chief Legal Officer) | Open-market sale | 1,690 | $170.81 | $288.7K | Form 4 |
| 2026-06-29 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion | 1,690 | $81.49 | $137.7K | Form 4 |
| 2026-06-29 | Lippoldt Darin | Officer (Chief Legal Officer) | Open-market sale | 8,110 | $170.03 | $1.38M | Form 4 |
| 2026-06-29 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion | 8,110 | $81.49 | $660.9K | Form 4 |
| 2026-06-26 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 200 | — | $0 | Form 4 |
| 2026-06-26 | Lippoldt Darin | Officer (Chief Legal Officer) | Open-market sale | 200 | $169.57 | $33.9K | Form 4 |
| 2026-06-26 | Lippoldt Darin | Officer (Chief Legal Officer) | Option exercise / conversion | 200 | $81.49 | $16.3K | Form 4 |
| 2026-06-05 | Onyia Jude | Officer (Chief Scientific Officer) | Bona fide gift | 2,441 | — | $0 | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Open-market sale | 1,843 | $167.31 | $308.4K | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Open-market sale | 5,829 | $166.56 | $970.9K | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Open-market sale | 6,896 | $165.79 | $1.14M | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Open-market sale | 2,549 | $164.44 | $419.2K | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Open-market sale | 7,883 | $163.81 | $1.29M | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Option exercise / conversion | 10,000 | $79.79 | $797.9K | Form 4 |
| 2026-06-05 | SHERWIN STEPHEN A | Director | Option exercise / conversion | 15,000 | $53.64 | $804.6K | Form 4 |
| 2026-06-04 | Norwalk Leslie V | Director | Open-market sale | 1,250 | $168.06 | $210.1K | Form 4 |
| 2026-06-02 | Keswani Sanjay Chandru | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,212 | — | $0 | Form 4 |
| 2026-06-02 | Keswani Sanjay Chandru | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 1,733 | $154.84 | $268.3K | Form 4 |
| 2026-06-02 | Keswani Sanjay Chandru | Officer (Chief Medical Officer) | Option exercise / conversion | 3,212 | — | $0 | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Option exercise / conversion (derivative) | 24,965 | — | $0 | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Open-market sale | 3,520 | $158.59 | $558.2K | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Open-market sale | 9,521 | $157.62 | $1.50M | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Open-market sale | 4,216 | $156.77 | $660.9K | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Open-market sale | 5,466 | $155.46 | $849.7K | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Open-market sale | 14,214 | $154.83 | $2.20M | Form 4 |
| 2026-06-02 | Cooke Julie | Officer (Chief Human Resources Officer) | Option exercise / conversion | 24,965 | $81.49 | $2.03M | Form 4 |
| 2026-06-01 | Onyia Jude | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 11,000 | — | $0 | Form 4 |
| 2026-06-01 | Onyia Jude | Officer (Chief Scientific Officer) | Open-market sale | 11,000 | $160.25 | $1.76M | Form 4 |
| 2026-06-01 | Onyia Jude | Officer (Chief Scientific Officer) | Option exercise / conversion | 11,000 | $84.74 | $932.1K | Form 4 |
| 2026-05-29 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion (derivative) | 2,261 | — | $0 | Form 4 |
| 2026-05-29 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Open-market sale | 2,261 | $156.71 | $354.3K | Form 4 |
| 2026-05-29 | Delaet Ingrid | Officer (Chief Regulatory Officer) | Option exercise / conversion | 2,261 | $79.02 | $178.7K | Form 4 |
| 2026-05-27 | Norwalk Leslie V | Director | Grant / award / vesting (derivative) | 2,624 | — | $0 | Form 4 |
| 2026-05-27 | Norwalk Leslie V | Director | Grant / award / vesting (derivative) | 1,284 | — | $0 | Form 4 |
| 2026-05-27 | RASTETTER WILLIAM H | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | MORROW GEORGE J | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | SHERWIN STEPHEN A | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | Sharp Shalini | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | POON CHRISTINE A | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | Mercier Johanna | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | LYONS GARY A | Director | Grant / award / vesting (derivative) | 2,624 | — | $0 | Form 4 |
| 2026-05-27 | LYONS GARY A | Director | Grant / award / vesting (derivative) | 1,284 | — | $0 | Form 4 |
| 2026-05-27 | POPS RICHARD F | Director | Grant / award / vesting (derivative) | 2,567 | — | $0 | Form 4 |
| 2026-05-27 | GORMAN KEVIN CHARLES | Director | Grant / award / vesting (derivative) | 5,248 | — | $0 | Form 4 |
| 2026-05-27 | Onyia Jude | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 11,000 | — | $0 | Form 4 |
| 2026-05-27 | Onyia Jude | Officer (Chief Scientific Officer) | Open-market sale | 11,000 | $155.53 | $1.71M | Form 4 |
| 2026-05-27 | Onyia Jude | Officer (Chief Scientific Officer) | Option exercise / conversion | 11,000 | $84.74 | $932.1K | Form 4 |
| 2026-05-26 | Boyer David W. | Officer (Chief Corp. Affairs Officer) | Open-market sale | 3,888 | $156.64 | $609.0K | Form 4 |
| 2026-05-21 | LYONS GARY A | Director | Option exercise / conversion (derivative) | 1,659 | — | $0 | Form 4 |
Ask the chat about NBIX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Neurocrine Biosciences (NBIX).
Last updated 2026-09-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.